ProShare Advisors
RUBY

ProShare Advisors’s Rubius Therapeutics, Inc RUBY Stock Holding History

ProShare Advisors’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-17,933
Closed -$98K – 2237
2022
Q1 		$98K Sell
17,933
-4,762
-21% -$30.2K ﹤0.01% 2038
2021
Q4 		$221K Sell
22,695
-2,371
-9% -$32.9K ﹤0.01% 1971
2021
Q3 		$448K Sell
25,066
-2,678
-10% -$58.3K ﹤0.01% 1273
2021
Q2 		$677K Buy
27,744
+6,942
+33% +$174K ﹤0.01% 1300
2021
Q1 		$551K Buy
20,802
+377
+2% +$5.51K ﹤0.01% 1377
2020
Q4 		$155K Buy
20,425
+3,015
+17% +$17.9K ﹤0.01% 1915
2020
Q3 		$87K Sell
17,410
-321
-2% -$1.7K ﹤0.01% 1537
2020
Q2 		$106K Buy
17,731
+4,693
+36% +$27.7K ﹤0.01% 1565
2020
Q1 		$58K Sell
13,038
-8,956
-41% -$66.5K ﹤0.01% 1110
2019
Q4 		$209K Sell
21,994
-3,546
-14% -$34.3K ﹤0.01% 1565
2019
Q3 		$200K Sell
25,540
-1,402
-5% -$16.3K ﹤0.01% 1445
2019
Q2 		$424K Sell
26,942
-3,617
-12% -$58.4K ﹤0.01% 1079
2019
Q1 		$553K Buy
30,559
+2,483
+9% +$38.1K ﹤0.01% 983
2018
Q4 		$451K Buy
+28,076
New +$512K ﹤0.01% 986

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AFM
Abbot Financial Management Andover, Massachusetts $239M AUM 27.19% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ProShare Advisors's RUBY Position: Q2 2022 in Review

ProShare Advisors sold out of Rubius Therapeutics, Inc (RUBY) in Q2 2022, closing a stake of 17,933 shares — an estimated $98K sold.

ProShare Advisors first reported a position in RUBY in Q4 2018 and held it in 14 quarters. The position peaked at $677K in Q2 2021. 72 funds tracked by Wall St. Rank hold RUBY as of Q2 2022.

  • ProShare Advisors reported no remaining Rubius Therapeutics, Inc position as of Q2 2022 after selling out during the quarter.
  • ProShare Advisors sold 17,933 Rubius Therapeutics, Inc shares in Q2 2022, an estimated $98K.
  • ProShare Advisors first reported a position in Rubius Therapeutics, Inc in Q4 2018 and held it in 14 quarters.
  • ProShare Advisors's Rubius Therapeutics, Inc position peaked at $677K in Q2 2021.
  • 72 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q2 2022.

Based on ProShare Advisors's 13F filing for Q2 2022, filed 1 Aug 2022.